Experimental Drug DNL343 Fails to Slow ALS Progression in Randomized Trial
A randomized clinical trial in JAMA Network Open found that 200 mg per day of DNL343, an eIF2B activator, did ...
A randomized clinical trial in JAMA Network Open found that 200 mg per day of DNL343, an eIF2B activator, did ...
A new review argues that stress granules and their RNA-binding proteins act as context-dependent modulators of cellular senescence and inflammation ...
Long-term treatment with the PKR inhibitor imoxin failed to reduce PKR activation, improve muscle function, or suppress inflammatory and ER ...
New research reveals that inflammatory macrophages fuel metastasis in triple-negative breast cancer by activating a stress-signaling pathway in tumor cells ...
In an exciting advancement for cancer therapeutics and cellular stress biology, a groundbreaking study has unveiled how WEE1 inhibitors activate ...
In the relentless pursuit of next-generation cancer therapies, a groundbreaking discovery has emerged from the laboratories of Wilson, Zhu, Vinciauskaite, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine